Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.
View all episodes
By BiotechTV
5
44 ratings
Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.
30,660 Listeners
1,890 Listeners
1,094 Listeners
325 Listeners
6,083 Listeners
61 Listeners
9,911 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
522 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners